Skip to content

RFA for Superficial Lipomas

Radiofrequency Ablation as a Scar-free, Non-operative Approach to Treatment of Superficial Lipomas

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06903208
Enrollment
10
Registered
2025-03-30
Start date
2025-04-02
Completion date
2027-07-01
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipoma

Keywords

lipoma, ablation, fatty tissue, fatty tumor, scarring, minimally invasive

Brief summary

Lipomas are non-cancerous growths of fatty tissue that develop under the skin in approximately 1 in 1000 people, though this number may be higher. While rarely symptomatic, they often cause emotional distress due to the unappealing appearance of the mass. Treatment of unsightly lipomas is excision with local anesthetic in the office or with sedation in the operating room. The recovery period is short and the procedure is low risk; however, the result of the operation is a visible scar over the site of the lipoma. Many patients defer surgical excision because excision of a lipoma is a cosmetic procedure, but the aesthetic outcome is undesirable. Radiofrequency ablation (RFA) is a technique that applies heat generated by a high frequency, alternating current to soft tissue. The hyperthermia produced by the current causes tissue necrosis that ablates the tissue into which the energy is directed. RFA has been successfully applied to thyroid nodules, pancreatic lesions, esophageal dysplasia and liver tumors. However, the manufacturers of the RFA technology have been focused on its application in pre-malignant and malignant lesions and have not yet considered its application to benign tumors. This study will test the success of RFA for superficial lipomas as a non-surgical option for treatment.

Interventions

DEVICESTARMed VIVA Combo RF System

RFA is a kind of treatment that uses a long thin needle, called a probe, to melt the lipoma. After numbing the skin with a local anesthetic, using an ultrasound machine as a guide, the study surgeon will insert the probe into the center of the lipoma. The probe will then deliver heat to the lipoma, melting it. The ultrasound is a machine which bounces sound waves to create an image that the study doctor sees on a screen. These ultrasound images will help the study surgeon to accurately guide the probe to the correct location of the lipoma. Once the lipoma is melted, the study surgeon will aspirate any residual liquid out.

Sponsors

Columbia University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years old * Patients with a lipoma \<5 cm, above the fascia on the trunk, abdomen or extremities

Exclusion criteria

* Lipomas of the face or neck * Angiolipomas (identified on exam as a firm, mobile, occasionally discolored mass) * Patients with history of hereditary retinoblastoma, Li-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis, tuberous sclerosis and Werner syndrome * A history of exposure to herbicides, arsenic and dioxin * A history of radiation treatment for other cancers

Design outcomes

Primary

MeasureTime frameDescription
Patient Satisfaction1 month, 6 months and 12 months post-procedurePatient satisfaction will be measured by self-reporting on a Likert scale asking whether they would recommend the procedure: "On a scale of 1 (would not recommend) to 5 (would highly recommend), how likely would you be to recommend RFA treatment of a lipoma to a friend?"
Change in Lesion VolumeBaseline, 1 month, 6 months and 12 months post-procedureLesion volume change from baseline to 1 year.

Secondary

MeasureTime frameDescription
Complication rate1 month, 6 months and 12 months post-procedureNumber of any complications after treatment.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKatherine Fischkoff, MD

Columbia University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026